By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...
In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...
Moderna (MRNA) shares reached a new 52-week high on Thursday as the COVID-19 vaccine maker extended its recent gains to ...
A large observational study using US healthcare claims and electronic health record data suggests that Moderna’s updated 2024 ...
CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...
CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine remained 93% effective against symptomatic illness six months after the second dose, but amid the ongoing spread of the highly contagious delta variant, ...
CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback